Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events

Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events

Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma. Many immune-related adverse events (irAEs) associated with nivolumab have been reported, such as pneumonitis, hepatitis, dermatitis, and thyroiditis. Prednisolone can effectively treat irAEs. However, i...

Full description

Bibliographic Details
Main Authors: Keisuke Imafuku, Koji Yoshino, Kei Yamaguchi, Satoshi Tsuboi, Kuniaki Ohara, Hiroo Hata
Format: Article
Language:English
Published: Karger Publishers 2017-04-01
Series:Case Reports in Oncology
Subjects:
Immune-related adverse event
Re-administration
Unresectable malignant melanoma
Cryptogenic organizing pneumonia
Diffuse alveolar damage
Pneumonitis
Nivolumab
Online Access:http://www.karger.com/Article/FullText/463379

Internet

http://www.karger.com/Article/FullText/463379

Similar Items